Published in Pharmacogenet Genomics on July 01, 2007
Inadequate responders to osteoporosis treatment: proposal for an operational definition. Osteoporos Int (2008) 1.68
From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev (2008) 1.35
A functional P2X7 splice variant with an alternative transmembrane domain 1 escapes gene inactivation in P2X7 knock-out mice. J Biol Chem (2009) 1.29
Long-term (trophic) purinergic signalling: purinoceptors control cell proliferation, differentiation and death. Cell Death Dis (2010) 1.19
Genetics of the P2X7 receptor and human disease. Purinergic Signal (2009) 1.19
Expression, signaling, and function of P2X7 receptors in bone. Purinergic Signal (2009) 1.13
Effect of P2X(7) receptor knockout on exocrine secretion of pancreas, salivary glands and lacrimal glands. J Physiol (2010) 1.12
Polymorphisms in the P2X7 receptor gene are associated with low lumbar spine bone mineral density and accelerated bone loss in post-menopausal women. Eur J Hum Genet (2012) 1.02
Transcriptional control mechanisms associated with the nucleotide receptor P2X7, a critical regulator of immunologic, osteogenic, and neurologic functions. Immunol Res (2011) 0.99
Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet (2012) 0.98
Insights into the Molecular Mechanisms Underlying Mammalian P2X7 Receptor Functions and Contributions in Diseases, Revealed by Structural Modeling and Single Nucleotide Polymorphisms. Front Pharmacol (2013) 0.97
Purinergic signalling in the musculoskeletal system. Purinergic Signal (2013) 0.93
Shockwaves induce osteogenic differentiation of human mesenchymal stem cells through ATP release and activation of P2X7 receptors. Stem Cells (2013) 0.92
The P2X7 Receptor is an Important Regulator of Extracellular ATP Levels. Front Endocrinol (Lausanne) (2012) 0.92
Association of P2X7 receptor polymorphisms with bone mineral density and osteoporosis risk in a cohort of Dutch fracture patients. Osteoporos Int (2012) 0.90
PKC-dependent ERK phosphorylation is essential for P2X7 receptor-mediated neuronal differentiation of neural progenitor cells. Cell Death Dis (2013) 0.90
Identification and characterization of a novel variant of the human P2X(7) receptor resulting in gain of function. Purinergic Signal (2009) 0.90
P2X7 Receptor Function in Bone-Related Cancer. J Osteoporos (2012) 0.89
C terminus of the P2X7 receptor: treasure hunting. Purinergic Signal (2011) 0.89
Association between P2X7 Receptor Polymorphisms and Bone Status in Mice. J Osteoporos (2012) 0.86
Cloning and pharmacological characterization of the dog P2X7 receptor. Br J Pharmacol (2009) 0.85
Functional polymorphisms in the P2X7 receptor gene are associated with osteoporosis. Osteoporos Int (2012) 0.85
The second transmembrane domain of P2X7 contributes to dilated pore formation. PLoS One (2013) 0.83
The P2X(7) loss-of-function Glu496Ala polymorphism affects ex vivo cytokine release and protects against the cytotoxic effects of high ATP-levels. BMC Immunol (2012) 0.83
Docking of competitive inhibitors to the P2X7 receptor family reveals key differences responsible for changes in response between rat and human. Bioorg Med Chem Lett (2015) 0.80
Effects of pulsed electromagnetic fields on human osteoblastlike cells (MG-63): a pilot study. Clin Orthop Relat Res (2010) 0.80
Non-synonymous single nucleotide polymorphisms in the P2X receptor genes: association with diseases, impact on receptor functions and potential use as diagnosis biomarkers. Int J Mol Sci (2014) 0.80
Genetic Background Strongly Influences the Bone Phenotype of P2X7 Receptor Knockout Mice. J Osteoporos (2012) 0.79
Gain and loss of function of P2X7 receptors: mechanisms, pharmacology and relevance to diabetic neuropathic pain. Mol Pain (2014) 0.79
Short- and long-term (trophic) purinergic signalling. Philos Trans R Soc Lond B Biol Sci (2016) 0.78
Tension force-induced ATP promotes osteogenesis through P2X7 receptor in osteoblasts. J Cell Biochem (2015) 0.78
The P2X7 receptor: a key player in immune-mediated bone loss? ScientificWorldJournal (2014) 0.78
Trophic activity of human P2X7 receptor isoforms A and B in osteosarcoma. PLoS One (2014) 0.78
Control of bone development by P2X and P2Y receptors expressed in mesenchymal and hematopoietic cells. Gene (2015) 0.77
Functional polymorphisms in the P2X7 receptor gene are associated with stress fracture injury. Purinergic Signal (2016) 0.76
Purinergic signalling in bone. Front Endocrinol (Lausanne) (2012) 0.76
A Candidate Gene Association Study of Bone Mineral Density in an Iranian Population. Front Endocrinol (Lausanne) (2016) 0.75
Pharmacogenomics in osteoporosis: Steps toward personalized medicine. Pharmgenomics Pers Med (2009) 0.75
Co-Expression of Wild-Type P2X7R with Gln460Arg Variant Alters Receptor Function. PLoS One (2016) 0.75
P2X7 receptor as a novel drug delivery system to increase the entrance of hydrophilic drugs into cells during photodynamic therapy. J Bioenerg Biomembr (2016) 0.75
Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2010) 6.00
Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2013) 5.76
Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ (2012) 5.63
Proton pump inhibitor use and the antifracture efficacy of alendronate. Arch Intern Med (2011) 2.98
Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum (2006) 2.82
Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study. J Bone Miner Res (2009) 2.65
Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med (2005) 2.60
Increased prevalence of celiac disease and need for routine screening among patients with osteoporosis. Arch Intern Med (2005) 2.52
Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. J Clin Endocrinol Metab (2010) 2.29
Excess mortality in men compared with women following a hip fracture. National analysis of comedications, comorbidity and survival. Age Ageing (2010) 2.15
Depression, antidepressants, and bone health in older adults: a systematic review. J Am Geriatr Soc (2014) 2.08
Low peak bone mass and attenuated anabolic response to parathyroid hormone in mice with an osteoblast-specific deletion of connexin43. J Cell Sci (2006) 2.06
Esophageal and gastric cancer incidence and mortality in alendronate users. J Bone Miner Res (2012) 1.70
Beta-catenin and BMP-2 synergize to promote osteoblast differentiation and new bone formation. J Cell Biochem (2005) 1.69
Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. Mol Biol Cell (2011) 1.63
The conditional connexin43G138R mouse mutant represents a new model of hereditary oculodentodigital dysplasia in humans. Hum Mol Genet (2007) 1.61
Gap junctions in skeletal development and function. Biochim Biophys Acta (2005) 1.53
Genetic and functional identification of the likely causative variant for cholesterol gallstone disease at the ABCG5/8 lithogenic locus. Hepatology (2013) 1.53
Attenuated response to in vivo mechanical loading in mice with conditional osteoblast ablation of the connexin43 gene (Gja1). J Bone Miner Res (2008) 1.51
Gap junctional communication modulates gene transcription by altering the recruitment of Sp1 and Sp3 to connexin-response elements in osteoblast promoters. J Biol Chem (2003) 1.50
More on reports of esophageal cancer with oral bisphosphonate use. N Engl J Med (2009) 1.50
Deletion of connexin43 in osteoblasts/osteocytes leads to impaired muscle formation in mice. J Bone Miner Res (2015) 1.50
One-year effects of vitamin D and calcium supplementation on chronic periodontitis. J Periodontol (2010) 1.49
Effects of dietary calcium compared with calcium supplements on estrogen metabolism and bone mineral density. Am J Clin Nutr (2007) 1.49
Targeted expression of a dominant-negative N-cadherin in vivo delays peak bone mass and increases adipogenesis. J Cell Sci (2004) 1.49
Television food advertising and the prevalence of childhood overweight and obesity: a multicountry comparison. Public Health Nutr (2009) 1.46
Tyrosine hydroxylase polymorphism (C-824T) and hypertension: a population-based study. Am J Hypertens (2010) 1.43
Vitamin D with calcium reduces mortality: patient level pooled analysis of 70,528 patients from eight major vitamin D trials. J Clin Endocrinol Metab (2012) 1.42
Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int (2009) 1.41
Cross-sectional study of vitamin D and calcium supplementation effects on chronic periodontitis. J Periodontol (2009) 1.40
Health-related quality of life in indigenous Sami schoolchildren in Sweden. Acta Paediatr (2014) 1.40
Risk assessment tools to identify women with increased risk of osteoporotic fracture: complexity or simplicity? A systematic review. J Bone Miner Res (2013) 1.38
Gap junctions regulate extracellular signal-regulated kinase signaling to affect gene transcription. Mol Biol Cell (2004) 1.33
N-cadherin in osteolineage cells is not required for maintenance of hematopoietic stem cells. Blood (2012) 1.33
Osteoblastic N-cadherin is not required for microenvironmental support and regulation of hematopoietic stem and progenitor cells. Blood (2012) 1.30
N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. J Cell Sci (2010) 1.26
At-risk variant in TCF7L2 for type II diabetes increases risk of schizophrenia. Biol Psychiatry (2011) 1.26
Do calcium plus vitamin D supplements increase cardiovascular risk? BMJ (2011) 1.25
Genotyping of the apolipoprotein B R3500Q mutation using immobilized locked nucleic acid capture probes. Clin Chem (2002) 1.25
Connexin43 deficiency reduces the sensitivity of cortical bone to the effects of muscle paralysis. J Bone Miner Res (2011) 1.23
Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. J Rheumatol (2008) 1.18
Longitudinal changes in leukocyte telomere length and mortality in humans. J Gerontol A Biol Sci Med Sci (2013) 1.18
Intercellular calcium signaling occurs between human osteoblasts and osteoclasts and requires activation of osteoclast P2X7 receptors. J Biol Chem (2001) 1.15
The health of young Swedish Sami with special reference to mental health. Int J Circumpolar Health (2012) 1.12
LNA-enhanced detection of single nucleotide polymorphisms in the apolipoprotein E. Nucleic Acids Res (2002) 1.09
The association between atopy and factors influencing folate metabolism: is low folate status causally related to the development of atopy? Int J Epidemiol (2006) 1.09
A randomized, placebo-controlled study of the effects of denosumab for the treatment of men with low bone mineral density. J Clin Endocrinol Metab (2012) 1.09
Bone loss after temporarily induced muscle paralysis by Botox is not fully recovered after 12 weeks. Ann N Y Acad Sci (2007) 1.09
Cell-cell adhesion and signaling through cadherins: connecting bone cells in their microenvironment. J Bone Miner Res (2006) 1.08
Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Saf (2007) 1.08
The impact of a TSH receptor gene polymorphism on thyroid-related phenotypes in a healthy Danish twin population. Clin Endocrinol (Oxf) (2007) 1.08
Findings of Danish study on risk of colon cancer in bisphosphonate users were misinterpreted. BMJ (2013) 1.06
Genetic and environmental influences of surfactant protein D serum levels. Am J Physiol Lung Cell Mol Physiol (2005) 1.06
Tibial loading increases osteogenic gene expression and cortical bone volume in mature and middle-aged mice. PLoS One (2012) 1.05
Accentuated ovariectomy-induced bone loss and altered osteogenesis in heterozygous N-cadherin null mice. J Bone Miner Res (2006) 1.05
Connexin-43 in the osteogenic BM niche regulates its cellular composition and the bidirectional traffic of hematopoietic stem cells and progenitors. Blood (2012) 1.05
Activation of L-type calcium channels is required for gap junction-mediated intercellular calcium signaling in osteoblastic cells. J Biol Chem (2002) 1.04
Maintaining the trust of physicians and the public in the medical literature: report of a task force on scientific publishing of clinical trials. J Bone Miner Res (2007) 1.03
Enhanced periosteal and endocortical responses to axial tibial compression loading in conditional connexin43 deficient mice. PLoS One (2012) 1.03
Serum 25(OH)D and type 2 diabetes association in a general population: a prospective study. Diabetes Care (2012) 1.03
Safety of bisphosphonates. Bone (2011) 1.02
Cell-cell interactions in regulating osteogenesis and osteoblast function. Birth Defects Res C Embryo Today (2005) 1.02
Cell-to-cell interactions in bone. Biochem Biophys Res Commun (2005) 1.02
Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. J Bone Miner Metab (2004) 1.01
The association of ADH and ALDH gene variants with alcohol drinking habits and cardiovascular disease risk factors. Alcohol Clin Exp Res (2008) 1.01
Safety issues with bisphosphonate therapy for osteoporosis. Rheumatology (Oxford) (2013) 1.00
Development of mice with osteoblast-specific connexin43 gene deletion. Cell Commun Adhes (2003) 1.00
Urokinase plasminogen activator receptor affects bone homeostasis by regulating osteoblast and osteoclast function. J Bone Miner Res (2007) 0.99
Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One (2012) 0.98
Genetic influences on mannan-binding lectin (MBL) and mannan-binding lectin associated serine protease-2 (MASP-2) activity. Genet Epidemiol (2007) 0.98
Single-nucleotide polymorphisms in the P2X7 receptor gene are associated with post-menopausal bone loss and vertebral fractures. Eur J Hum Genet (2012) 0.98
Vitamin D status and cause-specific mortality: a general population study. PLoS One (2012) 0.98
Vitamin D status and changes in cardiovascular risk factors: a prospective study of a general population. Cardiology (2012) 0.97
Heterogeneous nuclear ribonucleoprotein K represses transcription from a cytosine/thymidine-rich element in the osteocalcin promoter. Biochem J (2005) 0.97
Bisphosphonates improve trabecular bone mass and normalize cortical thickness in ovariectomized, osteoblast connexin43 deficient mice. Bone (2012) 0.96
Vitamin D status, filaggrin genotype, and cardiovascular risk factors: a Mendelian randomization approach. PLoS One (2013) 0.95
The predominant mechanism of intercellular calcium wave propagation changes during long-term culture of human osteoblast-like cells. Cell Calcium (2006) 0.94
Impact of two common polymorphisms in the PPARgamma gene on glucose tolerance and plasma insulin profiles in monozygotic and dizygotic twins: thrifty genotype, thrifty phenotype, or both? Diabetes (2003) 0.94
Microfibril-associated glycoprotein-1, an extracellular matrix regulator of bone remodeling. J Biol Chem (2010) 0.94
Health-related quality of life in girls and boys with juvenile idiopathic arthritis: self- and parental reports in a cross-sectional study. Pediatr Rheumatol Online J (2012) 0.93
Genomic approaches to identifying transcriptional regulators of osteoblast differentiation. Genome Biol (2003) 0.93
Studies of the Gly482Ser polymorphism of the peroxisome proliferator-activated receptor gamma coactivator 1alpha (PGC-1alpha) gene in Danish subjects with the metabolic syndrome. Diabetes Res Clin Pract (2005) 0.93
Vitamin D status and incident cardiovascular disease and all-cause mortality: a general population study. Endocrine (2012) 0.93
Patient satisfaction in postmenopausal women treated with a weekly bisphosphonate transitioned to once-monthly ibandronate. J Womens Health (Larchmt) (2009) 0.91
Syndrome of inappropriate ADH secretion and severe osteoporosis. J Clin Endocrinol Metab (2012) 0.91
Molecular mechanisms of osteoblast/osteocyte regulation by connexin43. Calcif Tissue Int (2013) 0.91
Gene expression profiles give insight into the molecular pathology of bone in primary hyperparathyroidism. Bone (2006) 0.90
Role of connexin43 in osteoblast response to physical load. Ann N Y Acad Sci (2006) 0.90
Season of birth and risk of atopic disease among children and adolescents. J Asthma (2007) 0.90
Bone mineral density and bone markers in patients with a recent low-energy fracture: effect of 1 y of treatment with calcium and vitamin D. Am J Clin Nutr (2007) 0.89
Tumor necrosis factor alpha is associated with insulin-mediated suppression of free fatty acids and net lipid oxidation in HIV-infected patients with lipodystrophy. Metabolism (2006) 0.89
Dominant negative N-cadherin inhibits osteoclast differentiation by interfering with beta-catenin regulation of RANKL, independent of cell-cell adhesion. J Bone Miner Res (2005) 0.88
Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals. AIDS (2014) 0.88
Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab (2002) 0.88
Recovery from SIADH-associated osteoporosis: a case report. J Clin Endocrinol Metab (2014) 0.87